Halberd

Halberd Equity

The The Equity of Halberd (HALB) as of Oct 10, 2026 is -913,113.00 USD. In the previous year, The Equity was -718,588.00 USD — a change of 27.07% (lower).

Equity

-913,113.00USD

YoY

27.07%

Last updated:

In 2025, Halberd's equity was -913,113.00 USD, a 27.07% increase from the -718,588.00 USD equity in the previous year.

The Halberd Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2017
-622,450.00 USD
Jan 1, 2019
-469,949.00 USD
Jan 1, 2020
-284,979.00 USD
Jan 1, 2021
-485,358.00 USD
Jan 1, 2022
-727,914.00 USD
Jan 1, 2023
-926,366.00 USD
Jan 1, 2024
-718,588.00 USD
Jan 1, 2025
-913,113.00 USD
The Halberd Equity history
YEAREquityYoY
-913,113.00USD+27.07%
-718,588.00USD-22.43%
-926,366.00USD+27.26%
-727,914.00USD+49.97%
-485,358.00USD+70.31%
-284,979.00USD-39.36%
-469,949.00USD-24.50%
-622,450.00USD-1.06%
-629,092.00USD—
Access this data via the Eulerpool API

Halberd Stock analysis

What does Halberd do? The Halberd Corp is an American company founded in 1987 and based in New York. It is a high-tech company focused on the development of medical technologies. Since its inception, the company has developed numerous innovative products and technologies that are used worldwide. A significant portion of Halberd Corp's business model focuses on providing medical products and solutions for various diseases. The main divisions of the company are biotechnology and pharmaceuticals, medical respiratory protection, medical technology, and the development of antibodies and diagnostics. Some of the most well-known products of Halberd Corp are the Medical Respiratory Masks, which were of great importance during the COVID-19 pandemic. These masks were developed and distributed worldwide by the company with innovative technology and the highest quality standards. The company has also developed various medical devices such as infusion pumps, blood pressure monitors, and various diagnostic devices that have been used by hospitals and care facilities. Another important business area of Halberd Corp is biotechnology and pharmaceuticals. In this field, the company specializes in developing new drugs and therapies for various diseases. The company has developed a range of proprietary medications that are used in the treatment of various diseases. Halberd Corp is also known for its development of antibodies and diagnostics and offers corresponding test kits. In recent years, Halberd Corp has formed numerous partnerships with other companies and institutions to bring its innovations to the market and market them. The company is also known for its successful joint ventures with other companies in the healthcare sector. Overall, Halberd Corp is an innovative company focused on medical technologies. With its presence in various areas of the healthcare industry, the company is able to develop new products and solutions that have the potential to improve and save lives. Halberd is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Halberd's Equity

Halberd's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Halberd's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Halberd's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Halberd's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Halberd’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Halberd stock

The Equity of Halberd is -913,113.00 USD in 2025.

The Equity of Halberd changed from -718,588.00 USD to -913,113.00 USD, representing a 27.07% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Halberd since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Halberd historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Halberd

All Key Metrics — Halberd